BI 1831169

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Solid Tumors

Phase 1

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

RecruitingNCT05155332

Boehringer IngelheimSolid Tumors

Start: 2022-03-28End: 2028-10-31Target: 190Updated: 2026-03-31

A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

Not yet recruitingNCT07176975

Boehringer IngelheimSolid Tumors

Start: 2026-06-01End: 2029-05-30Target: 46Updated: 2026-03-31

Related Papers

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer

Future Oncology2023-05-185 citations

628 Trial in progress: phase I dose-escalation study of VSV-GP (BI 1831169) monotherapy and with ezabenlimab (BI 754091) in patients with locally advanced or metastatic solid tumors

Regular and Young Investigator Award Abstracts2022-11-01

Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.

2022-06-1420 citations